Molecular genetics of human leukemias: New insights into therapy

Seminars in Hematology

Volumn 39, Issue 4 SUPPL. 3, 2002, Pages 6-11

  Gilliland, D Gary ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; TYROSINE KINASE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVATION; FUSION GENE; HUMAN; KARYOTYPE; LEUKEMOGENESIS; MOLECULAR CLONING; MOLECULAR GENETICS; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR DIFFERENTIATION;

EID: 0036814971     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.36921     Document Type: Article

References (45)

1. Lutterbach B, Hiebert SW: Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene 245:223-235, 2000
2. Pandolfi PP: Transcription therapy for cancer. Oncogene 20:3116-3127, 2001
3. Alcalay M, Orleth A, Sebastiani C, et al: Common themes in the pathogenesis of acute myeloid leukemia. Oncogene 20:5680-5694, 2001
4. Kantarjian HM, Faderl S, Talpaz M: Chronic myelogenous leukemia, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (Ed 6). Philadelphia, PA, Lippincott, Williams & Wilkins, 2001, pp 2433-2465
5. bcr/abl gene of the Philadelphia chromosome. Science 247:824-830, 1990
6. Ross TS, Gilliland DG: Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor β receptor fusion protein. J Biol Chem 274:22328-22336, 1999
7. Golub TR, Barker GF, Lovett M, et al: Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307-316, 1994
8. Golub TR, Goga A, Barker GF, et al: Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 16:4107-4116, 1996
9. Liu Q, Schwaller J, Kutok J, et al: Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J 19:1827-1838, 2000
10. Ross TS, Bernard OA, Berger R, et al: Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor β receptor (PDGFβR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 91:4419-4426, 1998
11. Schwaller J, Parganas, E, Wang D, et al: Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6:693-704, 2000
12. Tomasson MH, Sternberg DW, Williams IR, et al: Fatal myeloproliferation, induced in mice by TEL/PDGFβR expression, depends on PDGFβR tyrosines 579/581. J Clin Invest 105:423-432, 2000
13. Scheinberg DA, Maslak P, Weiss M: Acute leukemias, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (Ed 6). Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 2404-2433
14. Castilla LH, Wijmenga C, Wang Q, et al: Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 87:687-696, 1996
15. Okuda T, van Deursen J, Hiebert SW, et al: AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330, 1996
16. Yergeau DA, Hetherington CJ, Wang Q, et al: Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 15:303-306, 1997
17. Golub TR, Barker GF, Bohlander SK, et al: Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 92:4917-4921, 1995
18. Meyers S, Lenny N, Hiebert SW: The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 15:1974-1982, 1995
19. Hiebert SW, Sun W, Davis JN, et al: The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 16:1349-1355, 1996
20. Lutterbach B, Westendorf JJ, Linggi B, et al: ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18:7176-7184, 1998
21. Castilla LH, Garrett L, Adya N, et al: The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet 23:144-146, 1999
22. Fenrick R, Amann JM, Lutterbach B, et al: Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol 19:6566-6574, 1999
23. Speck NA, Stacy T, Wang Q, et al: Core-binding factor: A central player in hematopoiesis and leukemia. Cancer Res 59:1789s-1793s, 1999 (suppl)
24. Higuchi M, O'Brien D, Kumaravelu P, et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t (8;21) acute myeloid leukemia. Cancer Cell 1:63-74, 2002
25. Ford AM, Ridge SA, Cabrera ME, et al: In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363:358-360, 1993
26. Gill Super HJ, Rothberg PG, Kobayashi H, et al: Clonal, nonconstitutional rearrangements of the MLL gene in infant twins with acute lymphoblastic leukemia: In utero chromosome rearrangement of 11q23. Blood 83:641-644, 1994
27. Megonigal MD, Rappaport EF, Jones DH, et al: t(11;22)(q23; q11.2) in acute myeloid leukemia of infant twins fuses MLL with hCDCrel, a cell division cycle gene in the genomic region of deletion in DiGeorge and velocardiofacial syndromes. Proc Natl Acad Sci USA 95:6413-6418, 1998
28. Wiemels JL, Ford AM, Van Wering ER, et al: Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 94:1057-1062, 1999
29. Song W-J, Sullivan MG, Legare RD, et al: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23:166-175, 1999
30. Osato M, Asou N, Abdalla E, et al: Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2αB gene associated with myeloblastic leukemias. Blood 93:1817-1824, 1999
31. Preudhomme C, Warot-Loze D, Roumier C, et al: High incidence of biallelic point mutations in the runt domain of AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 96:2862-2869, 2000
32. Yeoh AEJ, Williams K, Behm F, et al: Somatic mutations of the AML-1 gene are frequent in acute myeloid leukemia with FAB MO morphology. Blood 96:91a, 2000 (suppl 1, abstr 389)
33. Imai Y, Kurokawa M, Izutsu K, et al: Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 96:3154-3160, 2000
34. Pabst T, Mueller BU, Zhang P, et al: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nat Genet 27:263-270, 2001
35. Abu-Duhier FM, Goodeve AC, Wilson GA, et al: FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 111:190-195, 2000
36. Hayakawa F, Towatari M, Kiyoi H, et al: Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19:624-631, 2000
37. Mizuki M, Fenski R, Halfter H, et al: Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96:3907-3914, 2000
38. Schnittger S, Schoch C, Kern W, et al: FLT3 length mutations in AML: Correlation to cytogenetics, FAB-subtype, and prognosis in 652 patients. Blood 96:826a, 2000 (suppl 1, abstr 3569)
39. Kottaridis PD, Gale RE, Frew ME, et al: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759, 2001
40. Stirewalt DL, Kopecky KJ, Meshinchi S, et al: FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97:3589-3595, 2001
41. Dash A, Gilliland DG: Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol 14:49-64, 2001
42. Dash AB, Williams IR, Kutok JL, et al: BCR/ABL cooperates with NUP98/HOXA9 to cause CML blast crisis. Blood 98:117a-118a, 2001 (suppl 1, abstr 493)
43. Kantarjian H, Sawyers C, Hochhaus A, et al for the International STI571 Study Group: Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (ph+CML). Blood 96:470a, 2000 (suppl 1, abstr 2022)
44. Sawyers CL, Hochhaus A, Feldman E, et al: A phase II study to determine the safety and anti-leukemic effects of ST1571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis. Blood 96:503a, 2000 (abstr 2165)
45. Talpaz M, Silver RT, Druker BJ, et al: A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase. Blood 96:469a, 2000 (suppl 1, abstr 2021)